# US 2013/0157295 A1 · Xanthurenic acid derivative pharmaceutical compositions and methods related thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157295 A1
- Document ID: US20130157295A1
- Status: Published application
- Kind: A1
- Application number: 13/751,554
- Filed: 2013-01-28
- Published: 2013-06-20
- Earliest claimed: 2004-12-29
- Assignees: Naturon Pharmaceuticals, Inc.
- Inventors: Neal Bricker; Stewart Shankel; Christopher D. Cain; Mark Mitchnick; Michael Schmertzler
- Web page: https://patentgrep.com/patent/US20130157295A1

## CPC

- C07D 215/48: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/12: for electrolyte homeostasis
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/12: of the kidneys
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07H 17/02: Heterocyclic radicals containing only nitrogen as ring hetero atoms
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G06K 19/02: characterised by the selection of materials, e.g. to avoid wear during transport through the machine
- G06K 19/07749: {the record carrier being capable of non-contact communication, e.g. constructional details of the antenna of a non-contact smart card}
- G06K 19/0776: {the adhering arrangement being a layer of adhesive, so that the record carrier can function as a sticker}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G06K: GRAPHICAL DATA READING (image or video recognition or understanding G06V); PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS

## Abstract

The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I: or a prodrug or pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

## Claims

### Claim at position 1

-24. (canceled)

### Claim 25

An isolated antibody that specifically binds to xanthurenic acid-8-O-β-D-glucoside.

### Claim 26 (depends on 25)

The antibody of claim 25 which is a monoclonal antibody.

### Claim 27 (depends on 25)

The antibody of claim 25 which is a polyclonal antibody.

### Claim 28

A diagnostic kit for assaying xanthurenic acid-8-O-β-D-glucoside in a serum sample, comprising one or more monoclonal antibodies directed against xanthurenic acid-8-O-β-D-glucoside.

### Claim 29

(canceled)

### Claim 30

A process for monitoring or detecting a disease associated with an abnormal level of xanthurenic acid-8-O-β-D-glucoside; the process comprising:
a. exposing a biological sample to a monoclonal antibody directed against xanthurenic acid-8-β-D-glucoside; and
b. detecting a level of xanthurenic acid-8-β-D-glucoside in said biological sample using the monoclonal antibody, wherein an elevated level of xanthurenic acid-8-O-β-D-glucoside in said biological sample is associated with the disease.

### Claim 31 (depends on 30)

The process of claim 30, wherein said disease is selected from the group consisting of hypertension, edema, acute renal failure, congestive heart failure, chronic renal failure, ascites, increased intra-ocular pressure, nephrotic syndrome or other disease state involving irregularities in fluid/sodium balance.

### Claim 32 (depends on 30)

The process of claim 30, wherein said biological sample is a urine sample.

### Claim 33 (depends on 30)

The process of claim 30, wherein said biological sample is a serum sample.

### Claim at position 11

-37. (canceled)